FDA Investigating Deaths Due to Acute Liver Failure in Non-ambulatory Duchenne Muscular Dystrophy Patients Following ELEVIDYS
Since approval, the FDA has received two reports of fatal acute liver failure following treatment of non-ambulatory pediatric male patients with DDMD with ELEVIDYS, an adeno-associated virus vector-based gene therapy.
Recommend0 recommendationsPublished in US National Health Agency Sources